| From a pill for longevity to a personal reserve of stem cells, David Duncan explores the pros and cons of the potential treatments that could let us live to 164. |
, David Ewing Duncan asked 30,000 people, with surprising results.His new book, When I'm 164: The New Science of Radical Life Extension, and What Happens If It Succeeds
Duncan describes the increasingly legitimate science of radical life extension—from Genetics and Regeneration to Machine Solutions—and considers the pluses and minuses of living to age 164, or beyond: everything from the impact on population and the cost of living to what happens to love, curiosity, and health.Concluding that anti-aging technologies will probably succeed in the next 30-50 years, he brings us back to the age-old question: "will you still need me, will you still feed me, when I'm..."
Duncen is the Founding Director of the Center of Life Science Policy at UC Berkeley and has taught at Singularity University. He has been a commentator on NPR's Morning Edition, and a contributing editor for Wired, Discover and Conde Nast Portfolio. He is a former special correspondent and producer for ABC Nightline and a correspondent for NOVA's ScienceNOW! David has won numerous awards including the Magazine Story of the Year from the American Association for the Advancement of Science. His articles have twice been cited in nominations for National Magazine Awards, and his work has appeared twice in The Best American Science and Nature Writing.
SOURCE TEDx Talks
SOURCE TEDx Talks
| By 33rd Square | Subscribe to 33rd Square |
0 comments:
Post a Comment